UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
These data suggest that MDMA-AT reduced PTSD symptoms and functional impairment in a diverse population with moderate to severe PTSD and was generally well tolerated." MAPS say that they now expect to submit a New Drug Application to the FDA later this year.
MAPS PBC completes second phase 3 “MAPP2” trial of MDMA-assisted therapy for treatment of PTSD
The top-line results are expected in the first quarter of 2023.
The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: A modeling study
Expanding access to MDMA-AT to patients with chronic and severe PTSD will provide substantial health and financial benefits.
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective, while delivering substantial clinical benefit.
Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy.
Here is an interesting part of the scientific discussion triggered by the immensely successful MAPS study on MDMA-assisted therapy for PTSD.
Relational and growth outcomes following couples therapy with MDMA for PTSD
mdma couples therapy for ptsd
Efficacy and safety results from the first pivotal phase 3 randomized controlled trial of MDMA-assisted psychotherapy for treatment of severe chronic PTSD
phase 3 randomized controlled trial of MDMA-assisted psychotherapy for treatment of severe chronic PTSD